General
Preferred name
PRELADENANT
Synonyms
SCH-420814 ()
SCH 420814 ()
Privadenant, SCH 420814, MK-3814 ()
MK-3814 ()
P&D ID
PD051735
CAS
377727-87-2
Tags
available
drug candidate
Drug indication
Parkinson disease
Drug Status
investigational
Max Phase
Phase 3
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Preladenant (SCH 420814) was an adenosine A2A receptor antagonist being developed for Parkinson's disease. Promising Phase 2 trial results did not translate to a significant effect over placebo in Phase 3 trial. Development has been discontinued. (GtoPdb)
Cell lines
0
Organisms
1
Compound Sets
11
Cayman Chemical Bioactives
22210
ChEMBL Drugs
CHEMBL240624
Drug Repurposing Hub
DrugBank
DB11864
DrugMAP
DMMWCZS
Guide to Pharmacology
5614
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL240624
MedChem Express Bioactive Compound Library
HY-10889
ReFrame library
Selleckchem Bioactive Compound Library
preladenant
TargetMol Bioactive Compound Library
T4290
External IDs
25
Properties
(calculated by RDKit )
Molecular Weight
503.24
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
1
Rotatable Bonds
9
Ring Count
6
Aromatic Ring Count
5
cLogP
2.16
TPSA
125.0
Fraction CSP3
0.36
Chiral centers
0.0
Largest ring
6.0
QED
0.3
Structural alerts
1
anil_di_alk_C(246)
c:1:c:c(:c:c:c:1-[#8]-[#6;X4])-[#7;$([#7!H0]-[#6;X4]),$([#7](-[#6;X4])-[#6;X4])]
PAINS Family A
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Target
A2A
ADORA1, ADORA2A, ADORA2B, ADORA3
Adenosine Receptor
MOA
Adenosine Receptor antagonist
Source data